GSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...

US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...

1 Daratumumab, lenalidomide, bortezomib, and dexamethasone comprise the new category 1 preferred regimen for patients ...

Remdesivir plus dexamethasone vs dexamethasone alone reduces the risk of mortality among patients hospitalized with COVID-19.

The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab ...

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...

GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review a Biologics License Application, BLA, for Blenrep in combinations with bortezomib plus dexamethasone and ...

In Telangana's Khammam, the DCA raided a quack's clinic, seizing drugs without a license. The operation unveiled hazardous ...